Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

EBV reactivation serological profile in primary Sjogren's syndrome: an underlying trigger of active articular involvement?

Full text
Author(s):
Pasoto, Sandra Gofinet [1, 2] ; Natalino, Renato Romera [1] ; Chakkour, Henrique Pires [1] ; Trindade Viana, Vilma dos Santos [1] ; Bueno, Cleonice [1] ; Leon, Elaine Pires [1] ; Gualhardo Vendramini, Margarete Borges [1] ; Levy Neto, Mauricio [1] ; Bonfa, Eloisa [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Div Rheumatol, Fac Med, Hosp Clin, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Disciplina Reumatol, Fac Med, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: RHEUMATOLOGY INTERNATIONAL; v. 33, n. 5, p. 1149-1157, MAY 2013.
Web of Science Citations: 17
Abstract

Antibody to Epstein-Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjogren's syndrome (pSS) were not established. We evaluated 100 pSS patients (American-European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI). Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA. Patients and controls had comparable frequencies and mean levels of anti-VCA IgG (90 vs. 86.5 %, p = 0.501; 2.6 +/- A 1.1 vs. 2.5 +/- A 1.1 AU/mL, p = 0.737) and anti-EBNA-1 IgG (92 vs. 94.4 %, p = 0.576; 141.3 +/- A 69.8 vs. 135.6 +/- A 67.5 RU/mL, p = 0.464). Anti-VCA IgM was negative in all cases. Noteworthy, higher frequency and increased mean levels of anti-EA-D were observed in patients than controls (36 vs. 4.5 %, p < 0.0001; 38.6 +/- A 57.4 vs. 7.9 +/- A 26.3 RU/mL, p < 0.0001). Further analysis of patients with (n = 36) and without (n = 64) anti-EA-D revealed comparable age/gender/ethnicity (p a parts per thousand yen 0.551), current prednisone dose (4.8 +/- A 6.9 vs. 5.1 +/- A 10.4 mg/day, p = 0.319), and current uses of prednisone (52.8 vs. 37.5 %, p = 0.148) and immunosuppressants (44.4 vs. 31.3 %, p = 0.201). ESSDAI values were comparable (p = 0.102), but joint activity was more frequent (25 vs. 9.4 %, p = 0.045) in anti-EA-D positive patients. Anti-EA-D antibodies were not associated with anti-Ro/SSA (p = 1.000), anti-La/SSB (p = 0.652), rheumatoid factor (p = 1.000), anti-alpha-fodrin (p = 0.390) or antiphospholipid antibodies (p = 0.573), not suggesting cross-reactivity. The higher anti-EA-D frequency associated with joint activity raises the possibility that a subclinical EBV reactivation may trigger or perpetuate the articular involvement in pSS. (AU)

FAPESP's process: 10/10013-4 - Serum autoantibodies in primary Sjögren's syndrome: study of clinical associations and possible correlations with antibodies to viral antigens (EBV and HTLV-1)
Grantee:Sandra Gofinet Pasoto
Support type: Regular Research Grants
FAPESP's process: 10/13463-0 - Antiphospholipid antibodies in primary Sjogren's syndrome: prevalence and clinical associations
Grantee:Henrique Pires Chakkour
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 10/10017-0 - Serum Autoantibodies in Primary Sjögren's Syndrome: Study of Clinical Associations and Possible Correlations with Antibodies to Viral Antigens (EBV and HTLV-1)
Grantee:Renato Romera Natalino
Support type: Scholarships in Brazil - Scientific Initiation